Come see us at RECOMB 2022 5/22-5/25 in La Jolla, CA Poster #29 Florian Schmidt, PhD will be presenting on “Machine learning to predict viral specificity of CD8+ T cells from high throughput multi-omics data”. Click here to view our Poster at RECOMB 2022...
ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University. Read our paper here: Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent...
SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 – ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology, today announced that it has signed a...
SINGAPORE and SAN DIEGO – June 29, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has made three strategic additions to its global team to expand the use...
Michael Fehlings, PhD., ImmunoScape’s VP of Operations and Development, will be presenting on,”SARS-CoV-2 specific CD8+ T cell responses in convalescent COVID-19 individuals” on May 25 at 11:00-11:30 am PT. The CyTOF® Edge will be a half day virtual...
